Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.

Abstract

A multicenter nonrandomized study was designed to assess the efficacy (response rate and duration of relapse-free survival) and safety of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 200 mg/m2 given as a 3-hour intravenous infusion with premedication every 3 weeks, followed by mitoxantrone 12 mg/m2, given as an… (More)

Topics

Cite this paper

@article{Panagos1997TreatmentOA, title={Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.}, author={G E Panagos}, journal={Seminars in oncology}, year={1997}, volume={24 1 Suppl 3}, pages={S17-21} }